Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Pharmaceutical companies have shied away from larger deals in recent years, with the biggest so far in 2025 being Johnson & Johnson’s acquisition of Intra-Cellular Therapies for $14.6 billion.

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT ...

PARIS— Sanofi SA SAN 0.99% said Monday it would buy Belgian biotech Ablynx NV for €3.9 billion ($4.85 billion), the French drugmaker’s second acquisition this month after purchasing U.S ...

FLICKR, GATIS GRIBUSTS Pharmaceutical giants Sanofi and Celgene kicked off the week with two major biotech acquisitions. On Monday (January 22), New Jersey-headquartered Celgene announced its ...

(RTTNews) - Sanofi (SNYNF, SNY) is considering potential acquisitions of U.S. biotechnology companies including Principia Biopharma as it seeks treatments for clinical areas including multiple ...